Roivant Sciences
ROIV
399 hedge funds and large institutions have $11B invested in Roivant Sciences in 2025 Q4 according to their latest regulatory filings, with 109 funds opening new positions, 149 increasing their positions, 95 reducing their positions, and 40 closing their positions.
227% more call options, than puts
Call options by funds: $166M | Put options by funds: $50.8M
173% more first-time investments, than exits
New positions opened: 109 | Existing positions closed: 40
57% more repeat investments, than reductions
Existing positions increased: 149 | Existing positions reduced: 95
45% more capital invested
Capital invested by funds: $7.59B → $11B (+$3.45B)
18% more funds holding
Funds holding: 338 → 399 (+61)
0.29% less ownership
Funds ownership: 73.45% → 73.17% (-0.29%)
7% less funds holding in top 10
Funds holding in top 10: 15 → 14 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$309M |
| 2 |
Morgan Stanley
New York
|
+$277M |
| 3 |
Goldman Sachs
New York
|
+$170M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$136M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$98.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIAU
SB Investment Advisers (UK)
London,
United Kingdom
|
-$472M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$338M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$217M |
| 4 |
PSC
Patient Square Capital
Menlo Park,
California
|
-$85.1M |
| 5 |
SC
Stempoint Capital
New York
|
-$63.7M |
ROIV Hedge Fund Activity: Q4 2025 in Review
399 of the 8,265 institutional investors tracked by Wall St. Rank reported a position in Roivant Sciences (ROIV) for Q4 2025, worth a combined $11B — up 45% from $7.59B a quarter earlier.
Buyers outnumbered sellers: 109 funds opened new ROIV positions and 40 closed out — a net gain of 69 holders — while 149 added to existing stakes and 95 trimmed.
The largest buyer was UBS Group, adding an estimated $309M. The largest seller was SB Investment Advisers (UK), cutting an estimated $472M.
- 399 institutional investors held Roivant Sciences (ROIV) as of Q4 2025, up from 338 in Q3 2025.
- Funds reported $11B of Roivant Sciences stock for Q4 2025, up 45% quarter-over-quarter.
- 109 funds opened new Roivant Sciences positions in Q4 2025 and 40 closed out, a net change of +69 holders.
- The largest Roivant Sciences buyer in Q4 2025 was UBS Group, an estimated $309M added.
- The largest Roivant Sciences seller in Q4 2025 was SB Investment Advisers (UK), an estimated $472M sold.
Based on aggregated 13F filings for Q4 2025.